🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Risk Evaluation and Management in Heart Failure

Recruitingn/aAges 18 Years - anyAllRuijin Hospital
NCT02998788 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an prospective study conducted in a Chinese heart failure population. The study investigates the effects of cardiovascular disease risk factors such as lifestyle behaviors,biomarkers and intermediate diseases on heart failure prognosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * aged 18 and above * inpatient with one of the following clinical situations: * congestive heart failure (pulmonary edema,pulmonary congestion or peripheral edema) * cardiogenic shock * Insufficient high output cardiac * with impaired cardiac function diagnosed by echocardiography * able to provide informed consent Exclusion Criteria: * expressed refusal to participate in the baseline investigation or follow-up visits Severe co-morbidity associated with a reduction in life expectancy of less than 12 months
💊

What it tests

  • Not listed
📍

Where

1 site
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy